參考資料: 1. Lammers P and Op Ten Berg M. Phase III clinical trial with a new oral contraceptive containing 150 µg desogestrel and 20 µg ethinylestradiol. Acta Obstet Gynecol Scand. 1991;70:497-500.
2. Serfaty D and Vree ML. A comparison of the cycle control and tolerability of two ultra low-dose oral contraceptives containing 29 µg ethinylestradiol and either 150 µg desogestrel or 75 µg gestodene. The European Journal of Contraception & Reproductive Health Care. 1998;3(4):179-189. 3. Organon HK Mercilon package insert, January 2021